首页> 外文期刊>Gene therapy >Development of a modified selective amplifier gene for hematopoietic stem cell gene therapy.
【24h】

Development of a modified selective amplifier gene for hematopoietic stem cell gene therapy.

机译:用于造血干细胞基因治疗的改良选择性扩增子基因的开发。

获取原文
获取原文并翻译 | 示例
       

摘要

We have proposed a novel concept, ie selective expansion of transduced cells, to overcome the low efficiency of gene transfer into hematopoietic stem cells. Previously, a fusion gene encoding a chimeric receptor (DeltaGCRER) between the mouse granulocyte colony-stimulating factor receptor (G-CSFR) and the hormone-binding domain of rat estrogen receptor was constructed as a 'selective amplifier gene'. Although the chimeric gene conferred estrogen-inducible proliferation on the transduced Ba/F3 cells, it also mediated differentiation of the retrovirally transduced 32D cells upon estrogen treatment. Since only a growth signal is required for our purpose, we further modified the DeltaGCRER gene to attenuate its differentiation signal. Based on the observation that tyrosine-703 in wild-type G-CSFR plays a pivotal role in transmitting the differentiation signal, phenylalanine was substituted for this residue in DeltaGCRER. When the resultant selective amplifier gene (DeltaY703F-GCRER gene) was expressed in 32D cells, sustained growth was supported by estrogen, while differentiation was suppressed. These cells ceased to grow upon estrogen withdrawal and differentiated with G-CSF treatment. The present findings suggested that DeltaY703F-GCRER may have desirable properties as a selective amplifier for hematopoietic stem cell expansion and gene therapy.
机译:我们提出了一种新的概念,即转导细胞的选择性扩增,以克服基因转移到造血干细胞中的低效率。以前,在小鼠粒细胞集落刺激因子受体(G-CSFR)和大鼠雌激素受体的激素结合域之间编码嵌合受体(DeltaGCRER)的融合基因被构建为“选择性扩增基因”。尽管嵌合基因在转导的Ba / F3细胞上赋予了雌激素诱导的增殖作用,但它在雌激素处理后还介导了逆转录病毒转导的32D细胞的分化。由于只需要一个生长信号即可达到目的,因此我们进一步修饰了DeltaGCRER基因以减弱其分化信号。基于观察到野生型G-CSFR中的酪氨酸703在传递分化信号中起着关键作用,苯丙氨酸被DeltaGCRER中的该残基取代。当在32D细胞中表达所得的选择性扩增子基因(DeltaY703F-GCRER基因)时,雌激素支持持续生长,而分化受到抑制。这些细胞在雌激素撤药后停止生长,并通过G-CSF处理分化。目前的发现表明,DeltaY703F-GCRER作为造血干细胞扩增和基因治疗的选择性扩增子可能具有理想的特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号